title: Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease.
abstract: We aimed to examine risk of diabetes mellitus (DM) among older adults with Alzheimer's disease receiving 3 types of psychotropic drugs, that is, antipsychotics, antidepressants, and sedative anxiolytics. We retrospectively analyzed data from a hospital-based Clinical Research Center for Dementia of South Korea (CREDOS) study conducted between January 1, 2008 and December 31, 2012. Participants (n = 3042) with Alzheimer's disease were aged 65 or older and had no preexisting history of DM. Development of DM was identified using claims for initiating at least 1 prescription of antidiabetic medications or a diagnosis of DM during the follow-up period. Cox proportional hazards regression was used to demonstrate the Hazard ratio of DM in use of each psychotropic drug. Among the 3042 participants, 426 patients (14.0%) developed DM, representing an incidence rate of 5.2/100 person-years during an average 2.9 years of follow-up period. Among the 3 types of psychotropic drugs, antipsychotic users had a significantly higher risk of DM (hazard ratio = 1.74, 95% confidence interval = 1.10, 2.76) than nonusers, after adjusting covariates. Antidepressants and sedative anxiolytics did not achieve statistical significance. These results suggested that the diabetes risk was elevated in Alzheimer patients on antipsychotic treatment. Therefore, patients with Alzheimer's disease receiving antipsychotic treatment should be carefully monitored for the development of DM.
authors.affiliation: From the Department of Psychiatry, Ajou University School of Medicine (KJC, CHH, HWR, YKJ, ZKYL, JSN, SJS); Institute on Aging, Ajou University Medical Center (CHH, YL); Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon (YL); Department of Psychiatry, CHA University School of Medicine, CHA Hospital, Bundang (KSL); Health Insurance Policy Research Institute (JHB); Department of Psychiatry, National Medical Center, Seoul (HCK); Department of Neurology, Inha University College of Medicine, Incheon (SHC); Memory Impairment Center, Ajou University Hospital, Suwon (CHH); Department of Psychiatry, Asan Medical Center (SYK); Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine (DLN, SWS); and Department of Medicare Administration, Backseok Arts University, Seoul, South Korea (SL).
authors.forename: Ki Jung
authors.initials: KJ
authors.lastname: Chang
authors.forename: Chang Hyung
authors.initials: CH
authors.lastname: Hong
authors.forename: Yunhwan
authors.initials: Y
authors.lastname: Lee
authors.forename: Kang Soo
authors.initials: KS
authors.lastname: Lee
authors.forename: Hyun Woong
authors.initials: HW
authors.lastname: Roh
authors.forename: Joung Hwan
authors.initials: JH
authors.lastname: Back
authors.forename: Young Ki
authors.initials: YK
authors.lastname: Jung
authors.forename: Ki Young
authors.initials: KY
authors.lastname: Lim
authors.forename: Jai Sung
authors.initials: JS
authors.lastname: Noh
authors.forename: Hyun Chung
authors.initials: HC
authors.lastname: Kim
authors.forename: Seong Hye
authors.initials: SH
authors.lastname: Choi
authors.forename: Seong Yoon
authors.initials: SY
authors.lastname: Kim
authors.forename: Duk L
authors.initials: DL
authors.lastname: Na
authors.forename: Sang Won
authors.initials: SW
authors.lastname: Seo
authors.forename: Soojin
authors.initials: S
authors.lastname: Lee
authors.forename: Sang Joon
authors.initials: SJ
authors.lastname: Son
mesh_terms: D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy; D014151:Anti-Anxiety Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003920:Diabetes Mellitus / Q000139:chemically induced* / Q000453:epidemiology; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents